| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
57,730,000 |
| Market
Cap: |
2.72(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.81 - $51.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
25,576 |
| Total Buy Value |
$0 |
$0 |
$0 |
$460,861 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
23,326 |
23,901 |
25,384 |
| Total Sell Value |
$0 |
$582,962 |
$595,313 |
$621,008 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
4 |
5 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,072,605 |
|
9% |
|
| Bakker Lex |
SVP, Chief Development Officer |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,775 |
|
9% |
|
| Lundberg Sven Ante |
President, CEO & PFOOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,495 |
|
9% |
|
| De Kruif John |
SVP & Chief Technology Officer |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,537 |
|
9% |
|
| Throsby Mark |
EVP & Chief Scientific Officer |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,866 |
|
9% |
|
| Mehra Anand |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,961,039 |
|
9% |
|
| Liu Hui |
EVP, CBO & Head of Merus USOff |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,369 |
|
9% |
|
| Incyte Corp |
10% Owner |
– – • |
2019-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,200,000 |
|
9% |
|
108 Records found
|
|
Page 5 of 5 |
|
|
1.64 (3.37%) 
